HE4 Blood Test: How This Ovarian Cancer Marker Works and What Your Results Mean
November 10, 2026
The HE4 blood test measures a protein called human epididymis protein 4, and for many women with a pelvic mass or an ovarian cancer diagnosis, that one number can be important.
The HE4 test can help doctors judge whether or not a pelvic mass is cancerous and track how epithelial ovarian cancer responds to treatment. It is not a screening test, and it doesn’t work equally well for every type of ovarian cancer.
That last point matters. Ovarian cancer is the deadliest gynecologic cancer, and understanding what your tests can and can’t tell you is part of protecting yourself. So let’s break down how the HE4 blood test for ovarian cancer works, what your results may mean, and the questions worth bringing to your next appointment.
Sign up to receive vital updates through email, and learn how you can get involved. "*" indicates required fieldsStay informed
What is the HE4 Blood Test?
An HE4 blood test is a standard blood draw that measures how much human epididymis protein 4 is circulating in your bloodstream. No fasting or special preparation is usually required.
The name sounds strange for an ovarian cancer marker, and there’s a reason. Researchers first found HE4 in the epididymis, a part of the male reproductive tract. It’s produced by a gene called WFDC2.
So why does it matter for ovarian cancer? Healthy tissue in the respiratory and reproductive tracts makes small amounts of HE4, while many ovarian tumors make a lot of it. The tumor releases the protein into the blood, where a lab can measure it.
A research team first reported HE4 as a possible blood marker for ovarian cancer in 2003, and it has since become one of the most studied ovarian cancer biomarkers alongside CA-125.
What the HE4 Lab Test Involves
- Sample: blood drawn from a vein in your arm
- Prep: none in most cases, though it’s commonly advised to tell your provider about high-dose biotin supplements, which can interfere with some HE4 results.
- Where it’s run: HE4 needs specialized equipment, so your sample may be sent to a reference lab
- Turnaround: Usually one to three days
How the HE4 Blood Test for Ovarian Cancer Is Used
The HE4 blood test has two FDA-cleared jobs. Neither one is finding cancer in non-symptomatic women.
Monitoring Epithelial Ovarian Cancer
In 2008, the FDA cleared the HE4 test to help doctors check whether epithelial ovarian cancer has come back or is getting worse.
Your doctor orders HE4 and CA-125 testing before treatment to get a baseline. If both are elevated, they get rechecked at intervals afterward. Falling levels generally suggest the cancer is responding. Rising or flat levels may signal that it isn’t, or that it has come back.
One catch: if your HE4 is normal at diagnosis, the test isn’t useful for tracking your cancer. It only works as a monitoring tool when your tumor actually produces the protein.
This is part of the regular follow-up care many patients go through after treatment. Our guide to ovarian cancer recurrence covers what that monitoring looks like and what to do if your numbers start climbing.
Assessing a Pelvic Mass Before Surgery (ROMA)
In September 2011, the FDA cleared HE4 for use with CA-125 in the Risk of Ovarian Malignancy Algorithm, or ROMA.
ROMA plugs three things into a formula:
- Your HE4 level
- Your CA-125 level
- Whether you’re premenopausal or postmenopausal
The result is a score that places you at high or low likelihood of having a malignancy found at surgery. It’s meant for women over 18 who have a pelvic mass, have surgery planned, and haven’t yet been referred to an oncologist. The score has to be read alongside imaging and a clinical exam, never on its own.
Why does that matter so much? Because who does your surgery can shape your outcome. One review found better outcomes for ovarian cancer patients treated surgically by gynecologic oncologists. A high ROMA score is one more signal that you should be in specialist hands. (If you’re unsure, read our guide on when to see a gynecologic oncologist.)
In the 462-patient study the FDA reviewed, ROMA combined with a physician’s usual assessment had a sensitivity of 88.4%, a specificity of 67.2%, and a negative predictive value of 96.2%. In plain terms, it caught most cancers. But roughly one in three benign masses was still flagged as high risk.
HE4 Test vs. CA-125: Why Doctors Often Order Both
CA-125 has been the go-to ovarian cancer marker for decades, but it also has real blind spots. CA-125 is raised in about 80% of epithelial ovarian cancers overall, and in only about 50% of stage I cases. It can also climb because of benign conditions like endometriosis, fibroids, or even your period.
HE4 helps fill some of those gaps. Its biggest advantage is specificity, meaning it’s less likely to be elevated by non-cancerous gynecologic problems.
Endometriosis is a good example. According to research that studied women with a pelvic mass, endometriosis cases had some of the highest CA-125 levels among benign growths, but the lowest median HE4.
That pattern could help doctors tell an endometrioma apart from cancer, which matters a lot for younger women.
Here’s how the two tests compare at a glance:
- What they measure: The HE4 test measures human epididymis protein 4. The CA-125 test measures cancer antigen 125.
- Endometriosis: HE4 is rarely raised by endometriosis, while CA-125 often is.
- Mucinous tumors: HE4 is rarely elevated in mucinous tumors, and CA-125 is also less reliable for them.
- Age: HE4 tends to rise after menopause. CA-125 tends to run higher before menopause.
- FDA-cleared uses: Both help monitor epithelial ovarian cancer, and both feed into the ROMA score.
- Screening: Neither is approved to screen women who have no symptoms.
Comparing HE4 to CA-125
HE4’s biggest strength is fewer false alarms. CA-125 can rise because of common, harmless conditions like endometriosis, fibroids, and even menstruation; HE4 is much less affected by them.
A review of nine studies found HE4 correctly ruled out benign growths about 9 times out of 10. An earlier analysis of CA-125 put it closer to 3 out of 4. For a woman whose cyst turns out to be harmless, that difference can mean a less frightening road to an answer.
But a more reassuring test isn’t automatically a better one. When researchers tested HE4 on women with all kinds of pelvic masses, the result was different. That group included borderline tumors and cancers that had spread from other organs, much like what a doctor sees in everyday practice. HE4 didn’t outperform CA-125 overall. The same researchers pointed out that some earlier studies favoring HE4 had left those harder cases out.
Age plays a role, too. HE4 naturally rises after menopause, while CA-125 tends to run higher in younger women. In postmenopausal women, CA-125 did the better job. In premenopausal women, the two performed about equally. Researchers have suggested that looking at both together could help doctors tell endometriosis apart from cancer, a common question for younger women with a pelvic mass.
So what does this mean for you? Think of the two tests as complementary: each can pick up on things the other misses. That’s why doctors usually order them together, and why HE4 isn’t meant to be used on its own.
Can an HE4 Ovarian Cancer Test Screen for Cancer?
This is where a lot of online information gets it wrong.
It’s tempting to think a simple blood test could catch ovarian cancer early in women with no symptoms. We want that, too. But the HE4 ovarian cancer test isn’t recommended for screening, for a few reasons:
- It’s non-specific. Normal tissues make small amounts of HE4, and mild elevations show up in a range of non-cancerous conditions. The HE4 result should not be used as a cancer screening test.
- It’s weakest when it would matter most. HE4 and CA-125 both performed significantly worse in early-stage disease than in advanced disease. HE4 and ROMA had a low chance of success as screening markers.
- Normal doesn’t mean clear. HE4 levels within the reference range don’t rule out cancer, and an elevated result isn’t proof of malignancy.
Some researchers are more hopeful. One meta-analysis suggested HE4 could one day serve as an initial step in a screening strategy, but called for large, long-term studies first. Those answers don’t exist yet.
So for now, there is still no reliable screening test for ovarian cancer in the general population. Your best tool right now is knowing your body. Persistent bloating, pelvic or abdominal pain, feeling full quickly, and urinary changes are worth bringing to a doctor, especially if they’re new and don’t go away. Our guide to ovarian cancer symptoms breaks down what to watch for.
Understanding Your HE4 Lab Test Results
There’s no single “normal” HE4 number that applies to everyone. What counts as normal depends on the lab, the testing method, and, more than most people realize, your age.
HE4 naturally rises as women get older, and the climb speeds up after about age 55. In one study of asymptomatic women, researchers looked at the HE4 level that 95% of women at each age fell under. That level nearly doubled between age 30 and age 80. Smoking was also linked to higher HE4 levels.
This is why the researchers recommended judging HE4 against women of the same age rather than using one cutoff for everyone. It’s also why menopausal status is built into the ROMA formula. A result that looks a little high for a 35-year-old might be completely expected for a 70-year-old.
If your HE4 comes back flagged, ask your doctor what reference range your lab used and whether it accounts for your age.
Trends Matter More Than a Single Number
If you’re being monitored after treatment, the pattern of your HE4 results over time tells your care team far more than any one reading. Here’s what changes may suggest:
- Levels fall after treatment: usually a sign the treatment is working
- Levels stay flat or rise: the treatment may not be working as well as hoped
- Levels climb during follow-up: may mean the cancer has come back, and usually leads to more testing
Researchers are also studying whether HE4 can flag a recurrence earlier than CA-125, and whether high levels can help predict which cancers may resist platinum-based chemotherapy.
Also worth noting: HE4 results from different labs or testing methods can’t be directly compared, and switching mid-monitoring can lead to misreadings. If you’re tracking your HE4 over months or years, ask whether your tests will be run the same way each time.
Where the HE4 Test Falls Short: Not All Ovarian Cancers Are the Same
Ovarian cancer isn’t one disease. It’s a group of very different cancers, and HE4 doesn’t show up equally in all of them.
When researchers studied tumor tissue, nearly all serous and endometrioid ovarian cancers produced HE4. Only about half of clear cell cancers did, and none of the mucinous tumors tested. HE4 is also rarely raised in germ cell tumors.
If you’ve been diagnosed with mucinous ovarian cancer or clear cell ovarian cancer, ask your doctor whether HE4 is a useful marker for you at all.
Borderline Tumors Often Fly Under the Radar
In one study, borderline tumors had HE4 levels about half as high as slow-growing invasive cancers, and far lower than aggressive ones. On average, their levels landed just under a cutoff some researchers use to flag concern. That means a woman with a borderline ovarian tumor could easily get an HE4 result that looks reassuring.
Early-stage cancers followed the same pattern. HE4 levels in stage I cancers were roughly a quarter of those in stage III. The earlier the disease, the easier it is for HE4 to miss.
Scientists are now studying HE4 as more than a marker. Lab research suggests the protein may help tumors grow, spread, and resist chemotherapy, which has sparked interest in HE4 as a possible treatment target.
Questions to Ask Your Doctor About an HE4 Test
If an HE4 test is part of your care, consider asking:
- Why are you ordering an HE4 test, and how will the result affect my care?
- Is HE4 a useful marker for my type of ovarian tumor?
- Was my HE4 high before treatment? If not, how will we track my cancer instead?
- Will my HE4 tests always be run at the same lab, the same way?
- What was my ROMA score, and should a gynecologic oncologist do my surgery?
- Could anything else, like kidney problems, smoking, or supplements, be affecting my result?
The Bottom Line on the HE4 Blood Test
The HE4 blood test is a useful tool with real limits. It can help show whether a pelvic mass is likely to be cancer, point patients toward specialist surgeons, and track some ovarian cancers over time. Paired with CA-125, it gives doctors a fuller picture than either test alone.
But it isn’t a screening test. It can also miss mucinous, germ cell, and borderline tumors, as well as some early-stage cancers.
Knowing that helps you ask sharper questions and push for answers when something feels off. That kind of self-advocacy saves lives. So does research that finally gives rare ovarian cancers the attention they deserve.